From Patterson's 19 June 09 Research Note (page 10):
A study by Czerepak et Ryser established a biotech failure rate of 74% (although we would make the
observation that aspects of the treatment have been significantly de-risked, as a result of the current
widespread use of Artmether in tablet form). This implies a risk adjusted value for Eastland® of $0.26.
If phase III trials are successful and after other appropriate submissions (below uses FDA approvals
as a proxy albeit not relevant for ArtiMistTM), then Eastland® valuation would rise to ~$1.50 on a derisked
commercialised basis.
From Patterson's 19 June 09 Research Note (page 10):A study by...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.394M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| EMS (ASX) Chart |
Day chart unavailable